Abstract
A new 15-valent pneumococcal conjugate vaccine (PCV15) against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 11A, 14, 18C, 19A, 19F, 22F, and 23F has been developed using aluminum phosphate as an adjuvant. Using the rabbit model, immunogenicity of each serotype was evaluated by measuring antigen specific antibodies and functional antibody titers and comparing them to a control vaccine, Prevnar13®. Among the shared serotypes in both PCV15 and Prevnar13®, Type 3 and 23F in PCV15 exhibited a lower opsonic index than Prevnar13®. Conversely, the other types showed greater or nearly the same immunogenic effects. Type 11A and 22F are two additional serotypes included in PCV15, and only 22F showed a reasonable opsonic index compared with other types. Type 11A exhibited a basal level fold-increase in OPA; thus, we further optimized 11A as well as 3 and 23F by controlling the polysaccharide-to-protein conjugation ratio as a variable. Antibody levels and functional antibody activities were evaluated by ELISA and OPA, and improved levels of immunogenic activities were observed for all three serotypes. In this study, we propose a new PCV15 candidate, in which the common 13 serotypes and a licensed control vaccine have equivalent efficacy while two additional serotypes showed adequate immunogenicity in the rabbit model.
| Original language | English |
|---|---|
| Journal | Biologicals |
| DOIs | |
| Publication status | Published - 2019 Jan 1 |
Fingerprint
Keywords
- Enzyme-linked immunosorbent assay
- Immunogenicity
- Opsonophagocytic activity
- Polyvalent pneumococcal conjugate vaccine
ASJC Scopus subject areas
- Biotechnology
- Bioengineering
- Applied Microbiology and Biotechnology
- Immunology and Microbiology(all)
- Pharmacology
Cite this
Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity. / Lee, Chankyu; Choi, Seuk Keun; Kim, Rock Ki; Kim, Heeyoun; Whang, Yoon Hee; Pharm, H.; Cheon, Hyunwoo; Yoon, Do Young; Kim, Chan Wha; Baik, Yeong Ok; Park, Sung Soo; Lee, Inhwan.
In: Biologicals, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity
AU - Lee, Chankyu
AU - Choi, Seuk Keun
AU - Kim, Rock Ki
AU - Kim, Heeyoun
AU - Whang, Yoon Hee
AU - Pharm, H.
AU - Cheon, Hyunwoo
AU - Yoon, Do Young
AU - Kim, Chan Wha
AU - Baik, Yeong Ok
AU - Park, Sung Soo
AU - Lee, Inhwan
PY - 2019/1/1
Y1 - 2019/1/1
N2 - A new 15-valent pneumococcal conjugate vaccine (PCV15) against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 11A, 14, 18C, 19A, 19F, 22F, and 23F has been developed using aluminum phosphate as an adjuvant. Using the rabbit model, immunogenicity of each serotype was evaluated by measuring antigen specific antibodies and functional antibody titers and comparing them to a control vaccine, Prevnar13®. Among the shared serotypes in both PCV15 and Prevnar13®, Type 3 and 23F in PCV15 exhibited a lower opsonic index than Prevnar13®. Conversely, the other types showed greater or nearly the same immunogenic effects. Type 11A and 22F are two additional serotypes included in PCV15, and only 22F showed a reasonable opsonic index compared with other types. Type 11A exhibited a basal level fold-increase in OPA; thus, we further optimized 11A as well as 3 and 23F by controlling the polysaccharide-to-protein conjugation ratio as a variable. Antibody levels and functional antibody activities were evaluated by ELISA and OPA, and improved levels of immunogenic activities were observed for all three serotypes. In this study, we propose a new PCV15 candidate, in which the common 13 serotypes and a licensed control vaccine have equivalent efficacy while two additional serotypes showed adequate immunogenicity in the rabbit model.
AB - A new 15-valent pneumococcal conjugate vaccine (PCV15) against serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 11A, 14, 18C, 19A, 19F, 22F, and 23F has been developed using aluminum phosphate as an adjuvant. Using the rabbit model, immunogenicity of each serotype was evaluated by measuring antigen specific antibodies and functional antibody titers and comparing them to a control vaccine, Prevnar13®. Among the shared serotypes in both PCV15 and Prevnar13®, Type 3 and 23F in PCV15 exhibited a lower opsonic index than Prevnar13®. Conversely, the other types showed greater or nearly the same immunogenic effects. Type 11A and 22F are two additional serotypes included in PCV15, and only 22F showed a reasonable opsonic index compared with other types. Type 11A exhibited a basal level fold-increase in OPA; thus, we further optimized 11A as well as 3 and 23F by controlling the polysaccharide-to-protein conjugation ratio as a variable. Antibody levels and functional antibody activities were evaluated by ELISA and OPA, and improved levels of immunogenic activities were observed for all three serotypes. In this study, we propose a new PCV15 candidate, in which the common 13 serotypes and a licensed control vaccine have equivalent efficacy while two additional serotypes showed adequate immunogenicity in the rabbit model.
KW - Enzyme-linked immunosorbent assay
KW - Immunogenicity
KW - Opsonophagocytic activity
KW - Polyvalent pneumococcal conjugate vaccine
UR - http://www.scopus.com/inward/record.url?scp=85070502469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070502469&partnerID=8YFLogxK
U2 - 10.1016/j.biologicals.2019.07.005
DO - 10.1016/j.biologicals.2019.07.005
M3 - Article
JO - Biologicals
JF - Biologicals
SN - 1045-1056
ER -